This trial is testing a new imaging agent to see if it can detect which patients are responding to brain cancer radiation therapy, and to track changes in the brain metastases over time.
3 Primary · 2 Secondary · Reporting Duration: through study completion, an average of 1 year
20 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 1
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: